The Safety of Cadonilimab: A Systematic Review and Single-Arm Meta-Analysis.

ABSTRACT:

Introduction

Cadonilimab (AK104) is a bispecific antibody that simultaneously targets programmed cell death-1 and cytotoxic T-lymphocyte antigen-4. It has received approval for the treatment of cervical cancer and gastric/gastroesophageal junction cancer. This meta-analysis aims to assess cadonilimab's safety profile.

Methods

A systematic review of electronic databases was conducted to identify clinical trials that reported cadonilimab's safety data. Immune-related adverse events (irAEs) was the primary endpoint, and treatment-related adverse events (TRAEs) were the secondary endpoints. A single-group proportion meta-analysis was conducted by R software.

Results

A total of 1271 patients across more than five cancer types in 11 clinical trials were included in this stu

SUBMITTER: Zhang Z 

PROVIDER: S-EPMC12405967 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature